VBL Therapeutics Announces Initiation of Two Clinical Trials for VB-111, Targeted, Dual-Action, Anti-Angiogenic, Vascular Disruptive Agent for Cancer
1/31/2011 11:20:21 AM
TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers. The first, a Phase 2a study, will evaluate the efficacy and safety of VB-111 among patients with advanced differentiated thyroid cancer (DTC). The second trial, a Phase 1/2 trial, will evaluate the efficacy, tolerability and safety of VB-111 among patients with relapsed glioblastoma multiforme (GBM).
comments powered by